272 related articles for article (PubMed ID: 37461341)
1. The Development of HDAC and Tubulin Dual-Targeting Inhibitors for Cancer Therapy.
Nie J; Wu H; Luan Y; Wu J
Mini Rev Med Chem; 2024; 24(5):480-490. PubMed ID: 37461341
[TBL] [Abstract][Full Text] [Related]
2. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
Peng X; Sun Z; Kuang P; Chen J
Eur J Med Chem; 2020 Dec; 208():112831. PubMed ID: 32961382
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and mechanistic study of new dual targeting HDAC/tubulin inhibitors.
El-Zoghbi MS; Bass AK; A Abuo-Rahma GE; Mohamed MF; Badr M; Al-Ghulikah HA; Abdelhafez EM
Future Med Chem; 2024 Apr; 16(7):601-622. PubMed ID: 38436113
[No Abstract] [Full Text] [Related]
4. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
Wahi A; Jain P; Sinhari A; Jadhav HR
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
[TBL] [Abstract][Full Text] [Related]
5. Discovery of chiral 1,4-diarylazetidin-2-one-based hydroxamic acid derivatives as novel tubulin polymerization inhibitors with histone deacetylase inhibitory activity.
Tang H; Liang Y; Yu M; Cai S; Ding K; Wang Y
Bioorg Med Chem; 2023 Sep; 92():117437. PubMed ID: 37563016
[TBL] [Abstract][Full Text] [Related]
6. Design and biological evaluation of dual tubulin/HDAC inhibitors based on millepachine for treatment of prostate cancer.
Xie S; Leng J; Zhao S; Zhu L; Zhang M; Ning M; Zhao B; Kong L; Yin Y
Eur J Med Chem; 2024 Mar; 268():116301. PubMed ID: 38452727
[TBL] [Abstract][Full Text] [Related]
7. Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential.
Zhang C; Li HX; Man Y; Jiang ZH; Yin P; Yu K
J Physiol Pharmacol; 2024 Apr; 75(2):117-122. PubMed ID: 38736259
[TBL] [Abstract][Full Text] [Related]
8. Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency.
Pan Y; Hou H; Zhou B; Gao J; Gao F
Eur J Med Chem; 2023 Dec; 262():115879. PubMed ID: 37875056
[TBL] [Abstract][Full Text] [Related]
9. Dual-target inhibitors of colchicine binding site for cancer treatment.
Lu L; Li K; Pu J; Wang S; Liang T; Wang J
Eur J Med Chem; 2024 Aug; 274():116543. PubMed ID: 38823265
[TBL] [Abstract][Full Text] [Related]
10. Density functional theory (DFT) studies in HDAC-based chemotherapeutics: Current findings, case studies and future perspectives.
Khatun S; Bhagat RP; Amin SA; Jha T; Gayen S
Comput Biol Med; 2024 Jun; 175():108468. PubMed ID: 38657469
[TBL] [Abstract][Full Text] [Related]
11. Advances in targeting histone deacetylase for treatment of solid tumors.
Shi MQ; Xu Y; Fu X; Pan DS; Lu XP; Xiao Y; Jiang YZ
J Hematol Oncol; 2024 May; 17(1):37. PubMed ID: 38822399
[TBL] [Abstract][Full Text] [Related]
12. Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer.
Pramanik SD; Kumar Halder A; Mukherjee U; Kumar D; Dey YN; R M
Front Chem; 2022; 10():948217. PubMed ID: 36034650
[TBL] [Abstract][Full Text] [Related]
13. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
14. Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers.
Sanaei M; Kavoosi F
Adv Biomed Res; 2019; 8():63. PubMed ID: 31737580
[TBL] [Abstract][Full Text] [Related]
15. Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
Aboeldahab AMA; Beshr EAM; Shoman ME; Rabea SM; Aly OM
Eur J Med Chem; 2018 Feb; 146():79-92. PubMed ID: 29396364
[TBL] [Abstract][Full Text] [Related]
16. An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives.
Su M; Gong X; Liu F
Expert Opin Drug Discov; 2021 Jul; 16(7):745-761. PubMed ID: 33530771
[TBL] [Abstract][Full Text] [Related]
17. Selective class IIa HDAC inhibitors: myth or reality.
Di Giorgio E; Gagliostro E; Brancolini C
Cell Mol Life Sci; 2015 Jan; 72(1):73-86. PubMed ID: 25189628
[TBL] [Abstract][Full Text] [Related]
18. An update on the development on tubulin inhibitors for the treatment of solid tumors.
Yakkala PA; Rahaman S; Soukya PSL; Begum SA; Kamal A
Expert Opin Ther Targets; 2024 Mar; 28(3):193-220. PubMed ID: 38618889
[TBL] [Abstract][Full Text] [Related]
19. A novel aromatic amide derivative SY-65 co-targeted tubulin and histone deacetylase 1 with potent anticancer activity in vitro and in vivo.
Li YR; Liu FF; Liu WB; Zhang YF; Tian XY; Fu XJ; Xu Y; Song J; Zhang SY
Biochem Pharmacol; 2022 Jul; 201():115070. PubMed ID: 35526597
[TBL] [Abstract][Full Text] [Related]
20. Role of HDACs in normal and malignant hematopoiesis.
Wang P; Wang Z; Liu J
Mol Cancer; 2020 Jan; 19(1):5. PubMed ID: 31910827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
